EL PASO, Texas--(BUSINESS WIRE)--Premier Biomedical, Inc. (OTCQB:BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as potential novel therapies for neurofibromatosis, atherosclerosis and muscular dystrophy, announced today they have obtained exclusive rights to the recently issued U.S. patent, “Sequential Extracorporeal Treatment of Bodily Fluids” (US Patent #9,216,386, 12/22/15), covering the basic technology underpinning Premier’s on-going research into new, innovative treatments for many of today’s most debilitating diseases.
“Between this sequential extracorporeal therapy patent just issued, and the previously granted patent “Utilization of Stents for the Treatment of Blood Borne Carcinomas”
Premier Biomedical, Inc. intends to develop its proprietary methodology in which the pathologies are eradicated by sequentially dialyzing the patient’s blood extracorporeally (outside the body). This extracorporeal methodology has an enormous potential for dramatically decreasing any side effects in the treatment of ill patients. The estimated expenditures for cancer treatment in the U.S. in 2010 were approx. $124.5 Billion, and projected to rise to $158 - $175 Billion by 20201.
William A. Hartman, CEO and President of Premier Biomedical, stated that, “Between this sequential extracorporeal therapy patent just issued, and the previously granted patent “Utilization of Stents for the Treatment of Blood Borne Carcinomas” (US Patent #8,758,287: 6/24/14), I believe that we have a clear roadmap for potentially curing cancer, possibly at any stage, and even after extensive metastasis. These patents support our on-going experimentation and plans to present our stunning results to the American Association for Cancer Research (AACR) in April.” Contact Premier via email at pr@premierbiomedical.com or by phone at (PBI) MED-7033 / (724) 633-7033.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, initially targeting the treatment of cancer. The Company’s common stock trades on the Over-The-Counter Bulletin Board under the ticker symbol “BIEI.” http://www.premierbiomedicalinc.com/
Safe Harbor Notice
Statements made in this news release constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Premier Biomedical makes no guarantee of future performance and actual results could differ materially. Premier Biomedical, Inc. undertakes no obligation to revise or update these.
1 Cancer costs projected to reach at least $158 billion in 2020; Posted: January 12, 2011, http://www.cancer.gov/news-events/press-releases/2011/costcancer2020
Contacts
Premier Biomedical, Inc.
W. Hartman, 724-633-7033
